Introduction
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases. RA mainly affects joints leading to articular damage, disability and substantial morbidity. The aetiology of RA remains unknown, although the disease appears to be the result of a complex interaction between host genetic and environmental factors [1] . Among environmental factors, a role for viruses has been long postulated and endogenous retrovirus (HERV) is one potential candidate in this context.
HERVs endogenated through infection of germline cells give rise to viable progeny in a symbiotic relationship with the host [2] . Some HERVs confer biological benefits to humans [3] , while other HERVs, notably HERV-K, may be deleterious to the host, retaining the capacity to replicate under select conditions and, consequently, the potential to trigger host innate and adaptive immune responses [2, 4] .
HERV-K (HML-2) is one of the most transcriptionally active in the endogenous viral family, and its members maintain open reading frames (ORF) in the genes gag, pol and env that are able to manufacture retroviral proteins and particles, and possibly complete virions [5] . HERV-K is divided into virus types 1 and 2. Type 1 virus encodes the oncogenic protein NP9, while type 2 virus produces Rec and Env proteins, both of which have been implicated in tumorigenesis [6] . The hypothesis of a potential pathogenic link between HERV-K and RA is based on several observations descending from both polymerase chain reaction (PCR)-based and serological studies [7] . The prevalence of insertionally polymorphic HERV-K was increased significantly in the RA population [8] . Moreover, a significantly increased expression has been demonstrated of HERV-K genes and transcription of viral proteins in peripheral blood, synovial fluid and synoviocytes of RA patients compared to healthy subjects [6, 9] . In addition, common amino acid sequences between HERV-K and host antigens have been reported in RA, suggesting that a mechanism of molecular mimicry may play a role in disease pathogenesis [10, 11] .
Considering this background, we performed an in-silico analysis to predict key antigenic regions of HERV-K on the basis of their putative ability in igniting an RA-specific humoral response. Candidate epitopes were then synthesized as short peptides, and an enzyme-linked immunosorbent assay (ELISA) was used to test the reactivity of RA and control serum to HERV-K peptides.
Materials and methods

Ethics approval
The study was approved by the Ethics Committee of ASL-1 Sassari ASL (Prot. 1192/L, 2014). The patients and volunteers gave written informed consent.
Subjects
Seventy consecutive unselected Sardinian patients with RA diagnosed according to the American College of Rheumatology criteria, referred to the out-patient clinic of the Rheumatology Unit at the Department of Clinical and Experimental Medicine of the University of Sassari (Italy), were recruited between March and April 2014 in this crosssectional case-control study. Seventy-one healthy sex-and age-matched subjects from the local blood donor bank were enrolled into the study as healthy controls (HC). All patients and controls lived in Sardinia. For each RA patient enrolled into the study, data regarding disease duration, disease activity, functional state and ongoing treatment were registered systematically. Disease activity was assessed using the Disease Activity Score-28 (DAS-28) and functional class by Health Assessment Questionnaire (HAQ). Demographic, clinical and laboratory characteristics of the participants are summarized in Table 1 .
Blood cell separation
Serum was isolated from heparinized peripheral blood samples by layering on Ficoll/Hypaque, as described elsewhere [12] .
Peptides
In-silico analysis performed using IEDB Analysis Resource software, in particular the Antibody Epitope Prediction, Bepipred linear epitope prediction software (http://www.iedb.org/home_v3.php), allowed us to identify different antigenic peptides derived from HERV-K env surface protein (UniProtKB Accession number: Q69384); four were selected for further analysis: HERV-K env 19-37 (VWVPGPTDDRCPAKPEEEG), HERV-K env [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] (RPKGKTCPKEIPKGSKNT), ERV-K env 164-186 (SGQTQSCP SAQVSPAVDSDLTES) and HERV-K env 205-226 (EKGISTPRP KIISPVSGPEHPE). All peptides were synthesized commercially (LifeTein, South Plainfield, NJ, USA) with a purity > 90% and kept frozen in single-use aliquots [10 mM] at 2808C.
ELISA
Indirect ELISA was carried out to detect specific antibodies against all synthetic peptides (assayed at 10 mg/ml) included into the study, as reported previously [2, 10] Ninety-six-well Nunc immunoplates were coated overnight at 48C with 10 mg/ml of peptides diluted in 0Á05 M carbonate-bicarbonate buffer, pH 9Á5 (Sigma, St Louis, MO, USA). Plates were then blocked for 1 h at room temperature with 5% non-fat dried milk (Sigma) and washed twice with phosphate-buffered saline (PBS) containing 0Á05% Tween-20 (PBS-T). Cerebrospinal fluid (CSF) samples were subsequently added at a 1 : 2 dilution in PBS-T for 2 h at room temperature, while sera were added at a 1 : 100 dilution. After five washes in PBS-T, 100 ml of alkaline phosphatase-conjugated goat anti-human immunoglobulin G polyclonal antibody (1 : 1000; Sigma) was added for 1 h at room temperature. Plates were washed again five times in PBS-T and para nitrophenylphosphate (Sigma) added as substrate for alkaline phosphatase. Plates were incubated at 
Statistical analysis
The analysis was performed using GraphPad Prism version 6.0 software. The Mann-Whitney test was performed for non-parametric comparisons. A value of P < 0Á05 was considered significant. Comparisons between RA patients and HC groups were performed using Fisher's exact test for non-parametric data, while receiver-operating characteristic (ROC) curves were utilized to evaluate the accuracy of the experiments. The optimal cut-off values were chosen according to ROC analysis, setting specificity at > 90% for all serum and CSF samples measured.
Results
ELISA
Antibodies against HERV-K env peptides were tested in serum of RA and HC samples.
HERV-K env-su 19-37 antibodies were above positivity in the sera of 19% RA patients and in only 3% of HCs (AUC 5 0Á84, RA versus HC P < 0Á0025) (Fig. 1a) .
Regarding HERV-K env-su 109-126 peptide, 9% of RA patients and 3% of HC were positive for antibodies in serum (P 5 0Á165, AUC 5 0Á71) (Fig. 1b) .
No statistical differences were found regarding positivity against HERV-K env-su in RA patients (3%) versus HC (3%) (AUC 5 0Á56, Fig. 1c) . HERV-K env-su peptide was recognized in the sera of 6% of RA patients and 3% of HC (P 5 0Á44, AUC 5 0Á75) (Fig. 1d) . No significant difference was found in the proportion of HERV-K env-su 19-37 antibody positivity according to disease activity (moderate-severe RA versus low activity and remission RA) and type of immunosuppressive treatment (Supporting information, Table S1 ). No correlation was found between HERV-K env-su 19-37 , antibody levels and RA descriptors [age, DAS-28, HAQ, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)] (Supporting information, Table S1 ). The same results were obtained with the other HERV-K env-su peptides tested (data not shown). The serum response of patients and controls towards all four epitopes is shown in Supporting information, Table S2 . No patient was positive to all four peptides tested; only four patients were positive to two peptides (HERV-K 109-126 and HERV-K 209-226 ) (Supporting information, Table S2 ).
Discussion
HERV-K mRNA transcripts and IgG anti-HERV-K antibodies have been associated with autoimmunity and cancers, as well as neurological conditions (e.g. multiple sclerosis) [2, 13, 14] . For the first time, we searched for a humoral response in patients with RA and controls against selected surface epitopes of HERV-K env-su (HERV-K env-su 19-37 , HERV-K env-su 109-126 and HERV-K env-su 209-226 ). Among them, the most interesting peptide was HERV-K env-su 19-37 , which was recognized in the sera of 19% of RA patients and in only 3% of controls.
HERV-K env-su 19-37 has a high homology with different human antigens, including myosin (with 61% of positive amino acids with sequence EAW76415.1) and netrin (73% of positive amino acids with sequence NP_006172.1). Evidence of a molecular mimicry as a pathogenic mechanism linking HERV-K to RA was provided by several groups. Freimanis and co-authors [10] demonstrated a significant humoral response in RA patients against one HERV-K epitope which shares residues with collagen type II, a common target of pathogenic RA autoantibodies. Similarly, IgGs against antigenic peptide on the matrix segment of HERV-K10 sharing common sequence with IgG1Fc, a target of rheumatoid factor, were demonstrated in RA patients [11] . An intriguing explanation of this result would be that the surface epitope HERV-K env-su 19-37 may function as an 'autoantigen' driving a secondary immunological response.
Unfortunately, we were unable to find any statistically significant correlation between antibody positivity and disease activity, systemic inflammation and type of immunosuppressive treatment. It may be possible that therapy could alter the humoral response. Notably, and also in the series of RA patients described by Nelson and co-authors, levels of antibodies to HERV-K antigens showed no correlation with RA disease activity [11] .
However, it should be remembered that a number of conditions, both genetic and environmental, may modulate HERV-K env protein transcription contributing to changes in the amount of immunological response. HERV-K transcription exhibits a significant increase in the presence of proinflammatory cytokines [tumour necrosis factor (TNF)-a and interleukin (IL)-6] in RA with regard to the general population [10] . Exogenous viruses such as Epstein-Barr virus (EBV), reported to be linked to RA [15] , may activate and stimulate HERV-K expression [16] . Moreover, differential HERV-K transcription has been shown to be regulated epigenetically by the degree of DNA methylation in RA [17] .
In conclusion, we have demonstrated a specific humoral response against a superficial envelope epitope of HERV-K in RA patients. Results of our study clearly add to the evidence for a possible role of HERV-K in RA pathogenesis. However, further data need to be provided to support molecular mimicry between HERV-K and host as one relevant mechanism of disease.
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